ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,709.54
0.01%
US Tech 100
19,331.20
0.42%
Dow Jones
42,196.52
0.09%
Brent Oil
74.57
0.20%
Bitcoin
60,861.03
0.05%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. AN2 Therapeutics Inc (ANTX)

  7. AN2 Therapeutics Inc (ANTX) News

ANTX

AN2 Therapeutics (ANTX)

AN2 Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ANTX
DateTimeSourceHeadlineSymbolCompany
08/28/20244:00PMBusiness WireAN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:ANTXAN2 Therapeutics Inc
08/19/20246:07AMEdgar (US Regulatory)Form 8-A12B - Registration of securities [Section 12(b)]NASDAQ:ANTXAN2 Therapeutics Inc
08/19/20246:04AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANTXAN2 Therapeutics Inc
08/16/20247:00AMBusiness WireAN2 Therapeutics Adopts Limited Duration Stockholder Rights PlanNASDAQ:ANTXAN2 Therapeutics Inc
08/13/20244:15PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ANTXAN2 Therapeutics Inc
08/13/20244:06PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANTXAN2 Therapeutics Inc
08/13/20244:01PMBusiness WireAN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific HighlightsNASDAQ:ANTXAN2 Therapeutics Inc
08/08/20244:50PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANTXAN2 Therapeutics Inc
08/08/20244:30PMBusiness WireAN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung DiseaseNASDAQ:ANTXAN2 Therapeutics Inc
07/12/20244:13PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANTXAN2 Therapeutics Inc
05/14/20244:12PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ANTXAN2 Therapeutics Inc
05/14/20244:07PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANTXAN2 Therapeutics Inc
05/14/20244:01PMEdgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:ANTXAN2 Therapeutics Inc
05/14/20244:01PMBusiness WireAN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific HighlightsNASDAQ:ANTXAN2 Therapeutics Inc
03/28/20244:10PMBusiness WireAN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific HighlightsNASDAQ:ANTXAN2 Therapeutics Inc
02/13/20245:11PMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ANTXAN2 Therapeutics Inc
02/12/20247:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANTXAN2 Therapeutics Inc
02/12/20246:45AMBusiness WireAN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung DiseaseNASDAQ:ANTXAN2 Therapeutics Inc
01/30/20244:10PMBusiness WireAN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences ConferenceNASDAQ:ANTXAN2 Therapeutics Inc
01/18/20246:19PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANTXAN2 Therapeutics Inc
01/17/20245:03PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANTXAN2 Therapeutics Inc
01/12/20245:08PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANTXAN2 Therapeutics Inc
01/11/20247:59PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANTXAN2 Therapeutics Inc
01/04/20246:06PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANTXAN2 Therapeutics Inc
01/04/20246:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANTXAN2 Therapeutics Inc
01/02/20244:45PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ANTXAN2 Therapeutics Inc
01/02/20244:36PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ANTXAN2 Therapeutics Inc
11/16/20236:57PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANTXAN2 Therapeutics Inc
11/09/20234:15PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ANTXAN2 Therapeutics Inc
11/09/20234:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANTXAN2 Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ANTX

Your Recent History

BIT
FHEALT
Vontobel Financial Produ...
BIT
UB5LXH
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved